DSP-2230

DSP-2230 is a selective, small-molecule Na_v1.7 and Na_v1.8 voltage-gated sodium channel blocker under development by Dainippon Sumitomo Pharma for the treatment of neuropathic pain. As of June 2014, it is in phase I/phase II clinical trials.

See also

References

This page contains text from Wikipedia, the Free Encyclopedia - https://wn.com/DSP-2230

Podcasts:

Email this Page Play all in Full Screen Show More Related Videos

Most Related
Most Recent
Most Popular
Top Rated

PLAYLIST TIME: